Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04502901 · ClinicalTrials.gov registry record · Phase 1
the Safety, Tolerability and PK of KX-826 in Healthy Males With Alopecia Following Topical Multiple Dose Ascending
A Phase 1 study, sponsored by Suzhou Kintor Pharmaceutical Inc,.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT04502901 is a Phase 1 study that has completed, run by Suzhou Kintor Pharmaceutical Inc,. The registered enrollment target is 40 participants.
The verdict
NCT04502901, a Phase 1 study, has completed, sponsored by Suzhou Kintor Pharmaceutical Inc,.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The study is a randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the safety, tolerability and PK of KX-826 following topical multiple ascending dose administration.
Interventions
- OTHER Placebo
- DRUG KX0826
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2020-01-14 |
| Est. Completion | 2021-01-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04502901
The ClinicalTrials.gov registry entry for NCT04502901 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Suzhou Kintor Pharmaceutical Inc,, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04502901 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04502901 about?
NCT04502901 is a clinical study titled "the Safety, Tolerability and PK of KX-826 in Healthy Males With Alopecia Following Topical Multiple Dose Ascending". The study is a randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the safety, tolerability and PK of KX-826 following topical multiple ascending dose administration.
What is the current status of trial NCT04502901?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2020-01-14. Estimated completion is 2021-01-15.
What interventions are being tested in trial NCT04502901?
The interventions under investigation include: Placebo (OTHER), KX0826 (DRUG).
Who is sponsoring clinical trial NCT04502901?
This trial is sponsored by Suzhou Kintor Pharmaceutical Inc,, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.